These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9570427)

  • 41. Effect of cilazapril on ventricular remodeling assessed by Doppler-echocardiographic assessment and cardiac gene expression.
    Yoshiyama M; Takeuchi K; Hanatani A; Shimada T; Takemoto Y; Shimizu N; Omura T; Kim S; Iwao H; Yoshikawa J
    Cardiovasc Drugs Ther; 1998 Mar; 12(1):57-70. PubMed ID: 9607133
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative effects of mibefradil and other calcium antagonists on resistance arteries of different end organs.
    van der Lee R; Pfaffendorf M; van Zwieten PA
    Fundam Clin Pharmacol; 1999; 13(2):198-203. PubMed ID: 10226764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction.
    Min JY; Sandmann S; Meissner A; Unger T; Simon R
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1038-44. PubMed ID: 10565822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine.
    Véniant M; Clozel JP; Hess P; Wolfgang R
    J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S55-8. PubMed ID: 1725005
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat.
    Sia YT; Lapointe N; Parker TG; Tsoporis JN; Deschepper CF; Calderone A; Pourdjabbar A; Jasmin JF; Sarrazin JF; Liu P; Adam A; Butany J; Rouleau JL
    Circulation; 2002 May; 105(21):2549-55. PubMed ID: 12034664
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
    Qiu CB; Qiu CS; Hess P; Clozel JP; Clozel M
    Acta Pharmacol Sin; 2001 Jun; 22(6):541-8. PubMed ID: 11747762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potent vasodilatory with minor cardiodepressant actions of mibefradil in human cardiac tissue.
    Brixius K; Mohr V; Müller-Ehmsen J; Hoischen S; Münch G; Schwinger RH
    Br J Pharmacol; 1998 Sep; 125(1):41-8. PubMed ID: 9776342
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of long-term treatment with trandolapril on sarcoplasmic reticulum function of cardiac muscle in rats with chronic heart failure following myocardial infarction.
    Yamaguchi F; Sanbe A; Takeo S
    Br J Pharmacol; 1998 Jan; 123(2):326-34. PubMed ID: 9489622
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Different effects of calcium antagonists on fluid filtration of large arteries and albumin permeability in spontaneously hypertensive rats.
    Lacolley P; Poitevin P; Koen R; Levy BI
    J Hypertens; 1998 Mar; 16(3):349-55. PubMed ID: 9557928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurohormonal activation in the treatment of congestive heart failure: basis for new treatments?
    Pool PE
    Cardiology; 1998 Jul; 90(1):1-7. PubMed ID: 9693163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action.
    Cao Z; Hulthén UL; Allen TJ; Cooper ME
    J Hypertens; 1998 Jun; 16(6):793-9. PubMed ID: 9663919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist.
    Abernethy DR
    Am J Cardiol; 1997 Aug; 80(4B):4C-11C. PubMed ID: 9286848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade.
    Ramires FJ; Sun Y; Weber KT
    J Mol Cell Cardiol; 1998 Mar; 30(3):475-83. PubMed ID: 9515025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.
    Tao ZW; Huang YW; Xia Q; Xu QW
    Chin Med J (Engl); 2005 Jan; 118(2):146-54. PubMed ID: 15667801
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Ro 40-5967, a new calcium antagonist, and enalapril on cardiac remodeling in renal hypertensive rats.
    Véniant M; Clozel JP; Heudes D; Banken L; Ménard J
    J Cardiovasc Pharmacol; 1993 Apr; 21(4):544-51. PubMed ID: 7681898
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
    van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
    Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of T channels in cardiovascular function.
    Hermsmeyer K
    Cardiology; 1998; 89 Suppl 1():2-9. PubMed ID: 9570423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.